BioTissue
- Company typePrivate
- Founded1997
- HeadquartersMiami, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
BioTissue firmographics
Firmographics- Name
- BioTissue
- Legal name
- BioTissue Holdings, Inc.
- Website
- https://biotissue.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BioTissue industry classification
Industry- Product category
- Regenerative Medicine Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)
- akta.pro secondary industries
- Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG)
Keywords
Where BioTissue is headquartered
LocationHeadquarters
- HQ city
- Miami
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioTissue business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Others
Revenue model
- Ocular Products Sales: BioTissue generates revenue through the sale of cryopreserved amniotic membrane products for ocular surface conditions. Products include Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard. Revenue is derived from healthcare providers including ophthalmologists, optometrists, and hospitals.
- Manufacturing Services: Following the divestiture of the surgical and wound care business to BioStem Technologies, BioTissue continues to manufacture the Neox and Clarix product lines for BioStem, generating manufacturing revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Direct purchase through BioTissue sales team |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
BioTissue product offering
Product offeringCore offering
BioTissue manufactures and sells cryopreserved human amniotic membrane and umbilical cord tissue allograft products processed using its proprietary CryoTek technology, primarily for the treatment of acute and chronic ocular surface conditions. The ocular portfolio includes the Prokera family of FDA-cleared therapeutic devices, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard, sold to ophthalmologists, optometrists, hospitals, and ambulatory surgery centers. Following the January 2026 divestiture of its surgical and wound care business to BioStem Technologies, BioTissue also generates contract manufacturing revenue by producing Neox and Clarix product lines for BioStem.
Product overview
BioTissue offers a portfolio of cryopreserved human birth tissue products for regenerative healing, with a primary focus on acute and chronic ocular surface conditions. The ocular portfolio centers on Prokera (the only FDA-cleared cryopreserved amniotic membrane therapeutic device, available in Classic, Slim, Plus, and Clear variants), alongside amniotic membrane allografts including CAM360 AmnioGraft, AmnioGraft, and AmnioGuard. All products are processed using the proprietary CryoTek cryopreservation technology, which preserves the tissue's structural and biological integrity including the HC-HA/PTX3 complex that orchestrates regenerative healing. In January 2026, BioTissue divested its Surgical and Wound Care business (Neox and Clarix product lines) to concentrate exclusively on ocular innovation.
Differentiator
Problem solved
Functional benefit
Brands
- Sharing Miracles: Birth tissue donation program facilitating voluntary donations from mothers within the United States
- CryoTek
- SteriTek
Products and services
- Prokera Prokera is a cryopreserved amniotic membrane therapeutic device that is FDA-cleared for anti-inflammation, anti-scarring, and promoting healing of damaged eye surfaces. It contains the only FDA-cleared cryopreserved amniotic membrane supporting the corneal-healing process. Available in Classic, Slim, Plus, and Clear variants to suit different clinical needs, Prokera is used by ophthalmologists and optometrists to treat ocular surface inflammation, scarring, and non-healing corneal defects.
- CAM360 AmnioGraft CAM360 AmnioGraft is a cryopreserved human amniotic membrane allograft with anti-inflammatory and anti-scarring properties used to help restore eye health. Shown to reduce signs and symptoms associated with Dry Eye Disease and optimize comfort for patients with early-stage dry eye and reduced corneal sensitivity. Processed with proprietary CryoTek cryopreservation technology.
- AmnioGraft AmnioGraft is a cryopreserved amniotic membrane tissue recognized by the FDA for unique anti-inflammatory, anti-scarring, and anti-angiogenic properties. Used by eye surgeons worldwide to protect, repair, and promote regenerative healing of damaged eye surfaces. Known as the 'Gold Standard' for ocular surface reconstruction.
- AmnioGuard AmnioGuard is an ultra-thick cryopreserved amniotic membrane with anti-inflammatory, anti-scarring, and anti-angiogenic properties. Used by eye surgeons to cover glaucoma shunt tubes and to protect, repair, and promote regenerative healing of damaged eye surfaces.
Quantifiable outcome
- 87% of employees report BioTissue as a great place to work (compared to 57% at typical US-based company)
- +3 more outcomes
Companies that use BioTissue
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
BioTissue technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BioTissue partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and minor.
- BioStem TechnologiesmajorBioStem Technologies acquired BioTissue's non-ocular Surgical and Wound Care business in January 2026 for up to $40 million, including $15 million upfront cash payment. BioTissue will continue manufacturing Neox and Clarix products for BioStem, while BioStem acquires exclusive rights to these product lines and BioTissue's surgical sales team. This divestiture allows BioTissue to concentrate on ocular innovation while enabling BioStem to expand in surgical and wound care.
- VizientmajorVizient is the nation's largest provider-driven healthcare performance improvement company working with more than 65% of hospitals across the US. BioTissue received its first-ever contract in the regenerative biologics category, providing Vizient hospital clients enhanced access to BioTissue's full portfolio including Clarix 1K.
- Donate Life AmericaminorBioTissue is a Donate Life Partner, working to raise public awareness about the importance of tissue donation and increase tissue donor registration through joint initiatives including Donate Life National Blue and Green Day celebrations.
- Mount Sinai Medical CenterminorBioTissue's Sharing Miracles program created a direct acquisition program with Mount Sinai Medical Center to expand birth tissue donation, enabling more patients to benefit from regenerative therapies.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
BioTissue competitors and assessment
Company assessmentDirect peers
- MiMedx Group: MiMedx is the leading publicly-traded competitor in amniotic membrane-based regenerative medicine, using dehydrated placental tissue (versus BioTissue's cryopreserved CryoTek process). Both companies sell similar allograft products to wound care, surgical, and ophthalmology markets, making MiMedx the most direct comparable peer.
- Organogenesis Holdings: Organogenesis is a regenerative medicine company offering bioengineered skin substitutes and wound care products that overlap with BioTissue's surgical and wound care applications prior to the BioStem divestiture. Both companies target similar hospital and surgical channels with biologic regenerative products.
- TissueTech: TissueTech is a privately-held competitor that markets dehydrated and cryopreserved amniotic membrane allograft products (e.g., AmnioFix) across ophthalmology, wound care, and musculoskeletal indications, directly competing with BioTissue's Neox, Clarix, and ocular product lines.
Emerging players
- BioStem Technologies: BioStem Technologies acquired BioTissue's non-ocular Surgical and Wound Care business (Neox and Clarix product lines) in January 2026 for up to $40M and now competes in adjacent wound care and surgical regenerative markets, with BioTissue continuing as a contract manufacturer.
- Corza Medical: Corza Medical is a surgical ophthalmology and specialty medical device company providing products for cataract, glaucoma, and vitreoretinal surgery. It is comparable to BioTissue through its ophthalmic surgical channel presence and overlapping customer base of ophthalmologists and ASCs.
Broad incumbents
- Integra LifeSciences: Integra LifeSciences is a diversified medical device company with a regenerative tissue technologies segment that includes dermal matrices, wound care, and surgical products. It competes broadly with BioTissue across hospital channels and shares Vizient/GPO contracting relationships.
- Smith+Nephew: Smith+Nephew is a large global medical device company with a substantial advanced wound management portfolio. While not specializing in amniotic membrane, it competes for hospital wound care budget and provides scale benchmarks for regenerative biologics distribution.
- MTF Biologics: MTF Biologics is one of the largest US tissue banks, providing a broad portfolio of allografts for sports medicine, wound care, and ophthalmology. It competes with BioTissue in sourcing donor tissue and serves overlapping surgical and ophthalmic customer segments through different processing approaches.
- AlloSource: AlloSource is a major nonprofit tissue bank producing allografts for orthopedic, spine, sports medicine, and wound care applications. As both a potential tissue supplier and competitor in regenerative biologics, AlloSource represents a comparable player in the donor tissue value chain.
- Bausch + Lomb: Bausch + Lomb is a major global ophthalmology company with a broad surgical, pharmaceutical, and consumer eye health portfolio. As a potential strategic acquirer and adjacent player serving the same ophthalmologist customer base, it represents the natural incumbent that could pursue BioTissue for inorganic growth in ocular surface biologics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioTissue social profiles
Digital presenceBioTissue compliance and trust
Trust signalCompliance2 records
BioTissue financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioTissue leadership team
Management profileNumber of profiles
Profiles7 records
BioTissue subsidiaries and ownership
Company hierarchySubsidiaries2 records
BioTissue funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioTissue M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioTissue
What does BioTissue do?
BioTissue manufactures and sells cryopreserved human amniotic membrane and umbilical cord tissue allograft products processed using its proprietary CryoTek technology, primarily for the treatment of acute and chronic ocular surface conditions. The ocular portfolio includes the Prokera family of FDA-cleared therapeutic devices, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard, sold to ophthalmologists, optometrists, hospitals, and ambulatory surgery centers. Following the January 2026 divestiture of its surgical and wound care business to BioStem Technologies, BioTissue also generates contract manufacturing revenue by producing Neox and Clarix product lines for BioStem.
Is BioTissue a public or private company?
BioTissue is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioTissue founded?
BioTissue was founded in 1997. It employs 11 to 50 people.
Where is BioTissue based?
BioTissue is headquartered in Miami, United States, in the North America region.
How does BioTissue make money?
Two revenue lines are on record. Ocular Products Sales are the primary driver. The others are manufacturing Services.
Who are BioTissue's main competitors?
Direct peers on record are MiMedx Group, Organogenesis Holdings and TissueTech. Emerging players are BioStem Technologies and Corza Medical. Broad incumbents are Integra LifeSciences, Smith+Nephew, MTF Biologics, AlloSource and Bausch + Lomb.
Does BioTissue have an API?
No public API is recorded for BioTissue.
What industry is BioTissue in?
BioTissue's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAAKAA, Biologic API/Drug Substance Manufacturing Services, with a secondary code of HLAAAKAB, Drug Product Fill-Finish & Aseptic Manufacturing Services. Its NAICS code is 325414 and its SIC code is 2836.